Sanofi to buy Bioverativ for $11.6bn
23-01-2018
USITC begins probe into CSL Behring
10-08-2017
Photobyphm / Shutterstock.com
Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix (coagulation factor IX (Recombinant), Fc fusion protein).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
haemophilia B, patent, patent infringement, CSL Behring, Bioverativ, biologics, Alprolix, Idelvion
